Filtered By:
Specialty: General Medicine
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 188 results found since Jan 2013.

Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack
CMAJ. 2023 Jul 10;195(26):E897-E904. doi: 10.1503/cmaj.230262.ABSTRACTBACKGROUND: Body mass index (BMI) may affect the response to platelet P2Y12 receptor inhibitors. We aimed to explore whether BMI influenced the efficacy and safety of ticagrelor and clopidogrel for secondary prevention of minor ischemic stroke or transient ischemic attack (TIA) among patients enrolled in the CHANCE-2 (Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II) trial.METHODS: In a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, we randomized patients ...
Source: cmaj - July 10, 2023 Category: General Medicine Authors: Jia Zhang Anxin Wang Xue Tian Xia Meng Xuewei Xie Jing Jing Jinxi Lin Yilong Wang Zixiao Li Liping Liu Hao Li Yong Jiang Xingquan Zhao Yongjun Wang Source Type: research

Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Authors: Rothlisberger JM, Ovbiagele B Abstract Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the cornerstone of secondary stroke prevention, and proven drugs available to successfully realize this therapeutic strategy for the long term include aspirin, dipyridamole plus aspirin and clopidogrel. However, government agencies, corporations, health plans and patients desire more information about the clinical- and cost-effectiveness of these established therapies in real-world settings. This paper provides an update on evidence-based secondary stroke prevention with antiplate...
Source: Journal of Comparative Effectiveness Research - December 2, 2015 Category: Journals (General) Tags: J Comp Eff Res Source Type: research

Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis
Conclusions Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack. Cilostazol was associated with a significantly lower bleeding risk than low-dose aspirin (75–162 mg daily) and aspirin (50 mg daily) plus dipyridamole (400 mg daily). Low-dose aspirin was as effective as higher daily doses. However, further large, randomised, controlled, head-to-head trials are needed, especially in non-Asian ethnic groups.
Source: BMJ Open - March 17, 2016 Category: Journals (General) Authors: Niu, P.-P., Guo, Z.-N., Jin, H., Xing, Y.-Q., Yang, Y. Tags: Open access, Evidence based practice, Neurology, Pharmacology and therapeutics Research Source Type: research

Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation
Conclusions Compared with standard adjusted dose VKA, new oral anticoagulants were associated with modest reductions in the absolute risk of stroke and major bleeding. People on antiplatelet drugs experienced more strokes compared with anticoagulant drugs without any reduction in bleeding risk. To fully elucidate the comparative benefits and harms of antithrombotic agents across the various subpopulations, rigorously conducted comparative studies or network meta-regression analyses of patient-level data are required. Systematic review registration number PROSPERO registry—CRD42012002721.
Source: BMJ Open - June 2, 2014 Category: Journals (General) Authors: Cameron, C., Coyle, D., Richter, T., Kelly, S., Gauthier, K., Steiner, S., Carrier, M., Coyle, K., Bai, A., Moulton, K., Clifford, T., Wells, G. Tags: Open access, Cardiovascular medicine, Epidemiology, Health policy Research Source Type: research

Comment Learning from TARDIS: time for more focused trials in stroke prevention
Antithrombotic therapy immediately following stroke is important to minimise the risk of recurrence, but the optimum choice and number of drugs to use are unclear, and efficacy in preventing thrombosis needs to be weighed against bleeding risk. In The Lancet, the TARDIS investigators report findings from a randomised trial1 that tested intensive antiplatelet therapy with three agents (aspirin, clopidogrel, and dipyridamole) against therapy based on current UK guidelines2 (either clopidogrel, or aspirin plus dipyridamole) for 30 days in patients with transient ischaemic attack (TIA) or ischaemic stroke.
Source: LANCET - December 20, 2017 Category: General Medicine Authors: Pierre Amarenco Tags: Comment Source Type: research

After ' Mini-Stroke, ' Drug Combo (Aspirin Plus Clopidogrel) Could Help Cut Odds for Major Attack
WEDNESDAY, May 16, 2018 -- A dual-drug approach after a " mini-stroke " might maximize a person ' s odds of avoiding a more major stroke in the months after, research shows. Minor strokes and events known as " transient ischemic attacks " (TIA), or...
Source: Drugs.com - Daily MedNews - May 16, 2018 Category: General Medicine Source Type: news

Blood Thinning Drug May Be Safer Option Against Recurrent Stroke
THURSDAY, Feb. 7, 2019 -- Taking the blood thinner Pletal (cilostazol) with either aspirin or clopidogrel (best known as Plavix) lowers stroke patients ' risk of a subsequent stroke better than taking aspirin or clopidogrel alone, a new study...
Source: Drugs.com - Daily MedNews - February 7, 2019 Category: General Medicine Source Type: news

Aspirin, Anti-Clotting Meds Safe After Bleeding Stroke: Study
WEDNESDAY, May 22, 2019 -- Taking aspirin or anti-clotting medicines like Plavix won ' t boost the risk of another stroke if you ' ve already survived a bleeding stroke, a new study suggests. In fact, they might even help guard against a second brain...
Source: Drugs.com - Daily MedNews - May 22, 2019 Category: General Medicine Source Type: news

Treatment of progressive ischemic stroke with low ‑dose eptifibatide: A retrospective case‑control study
Exp Ther Med. 2022 Nov 22;25(1):22. doi: 10.3892/etm.2022.11721. eCollection 2023 Jan.ABSTRACTProgressive ischemic stroke (PIS) is a therapeutic challenge in clinical practice. The present retrospective study aimed to investigate the safety and effectiveness of eptifibatide in the treatment of PIS. The present study enrolled patients with PIS admitted to Xiangtan Central Hospital (Xiangtan, China) between March 2020 and March 2021 with National Institutes of Health Stroke Scale (NIHSS) progression scores of ≥2 points during the initial 72 h. Patients were then divided into two groups according to their different anti-pla...
Source: Experimental and Therapeutic Medicine - December 23, 2022 Category: General Medicine Authors: Long Luo Jinsheng Lin Ye Deng Zhigang Li Ying Yuan Wen Zhang Source Type: research